Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
PBYI's Cash-to-Debt is ranked higher than
78% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. PBYI: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
PBYI' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Interest Coverage No Debt
PBYI's Interest Coverage is ranked higher than
71% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PBYI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PBYI' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 12.13
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE % -172.72
PBYI's ROE % is ranked lower than
89% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. PBYI: -172.72 )
Ranked among companies with meaningful ROE % only.
PBYI' s ROE % Range Over the Past 10 Years
Min: -172.72  Med: -106.94 Max: -37.64
Current: -172.72
-172.72
-37.64
ROA % -137.63
PBYI's ROA % is ranked lower than
89% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. PBYI: -137.63 )
Ranked among companies with meaningful ROA % only.
PBYI' s ROA % Range Over the Past 10 Years
Min: -1700  Med: -109.18 Max: -36.94
Current: -137.63
-1700
-36.94
ROC (Joel Greenblatt) % -6860.36
PBYI's ROC (Joel Greenblatt) % is ranked lower than
84% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. PBYI: -6860.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PBYI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -10585.02  Med: -7115.5 Max: -2978.59
Current: -6860.36
-10585.02
-2978.59
3-Year EBITDA Growth Rate 63.40
PBYI's 3-Year EBITDA Growth Rate is ranked higher than
93% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. PBYI: 63.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PBYI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 29.7  Med: 301.65 Max: 882.4
Current: 63.4
29.7
882.4
3-Year EPS without NRI Growth Rate 63.40
PBYI's 3-Year EPS without NRI Growth Rate is ranked higher than
93% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. PBYI: 63.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PBYI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 58.2 Max: 883
Current: 63.4
0
883
GuruFocus has detected 3 Warning Signs with Puma Biotechnology Inc $PBYI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PBYI's 10-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

PBYI Guru Trades in Q1 2016

Eaton Vance Worldwide Health Sciences Fund 142,000 sh (New)
John Paulson 70,300 sh (+52.83%)
Steven Cohen 1,157,700 sh (+22.45%)
Jeremy Grantham 2,010,801 sh (-30.66%)
» More
Q2 2016

PBYI Guru Trades in Q2 2016

John Paulson 145,800 sh (+107.40%)
Steven Cohen 1,415,800 sh (+22.29%)
Eaton Vance Worldwide Health Sciences Fund 142,000 sh (unchged)
Jeremy Grantham Sold Out
» More
Q3 2016

PBYI Guru Trades in Q3 2016

Jana Partners 76,074 sh (New)
Eaton Vance Worldwide Health Sciences Fund Sold Out
Steven Cohen 1,028,706 sh (-27.34%)
John Paulson 84,500 sh (-42.04%)
» More
Q4 2016

PBYI Guru Trades in Q4 2016

Jana Partners 142,727 sh (+87.62%)
Steven Cohen Sold Out
John Paulson 15,690 sh (-81.43%)
» More
» Details

Insider Trades

Latest Guru Trades with PBYI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:DERM, NAS:BPMC, NAS:BGNE, NYSE:AXON, NAS:LXRX, NAS:CORT, NAS:INVA, NAS:ARRY, NAS:RGEN, NYSE:EBS, NAS:FGEN, NAS:GBT, NAS:SRPT, NAS:XNCR, OTCPK:BVNRY, NAS:LOXO, NAS:AIMT, NAS:ONCE, NAS:INSM, NAS:CHRS » details
Traded in other countries:0PB.Germany,
Headquarter Location:USA
Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Puma Biotechnology is a biotechnology company focused on developing novel therapeutics for the treatment of cancer. Puma licenses the commercial rights to its current drug candidates. The company expects to augment its product pipeline by acquiring, through license or otherwise, additional drug candidates for research and development and potential commercialization. In evaluating potential drug candidates, Puma employs disciplined decision criteria favoring drug candidates that have undergone at least some clinical study.

Top Ranked Articles about Puma Biotechnology Inc

Sam Isaly Purchases Stake in Puma Biotechnology Company is close to 3-year low in price with no debt
Guru Samuel Isaly purchased a 142,000-share stake in Puma Biotechnology Inc. (NASDAQ:PBYI) in the first quarter. Read more...

Ratios

vs
industry
vs
history
PB Ratio 6.56
PBYI's PB Ratio is ranked lower than
73% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. PBYI: 6.56 )
Ranked among companies with meaningful PB Ratio only.
PBYI' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 7.9
Current: 6.56
0
7.9
EV-to-EBIT -4.17
PBYI's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. PBYI: -4.17 )
Ranked among companies with meaningful EV-to-EBIT only.
PBYI' s EV-to-EBIT Range Over the Past 10 Years
Min: -5.14  Med: 0 Max: 0
Current: -4.17
-5.14
0
EV-to-EBITDA -4.19
PBYI's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. PBYI: -4.19 )
Ranked among companies with meaningful EV-to-EBITDA only.
PBYI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -5.16  Med: 0 Max: 0
Current: -4.19
-5.16
0
Current Ratio 6.31
PBYI's Current Ratio is ranked higher than
64% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. PBYI: 6.31 )
Ranked among companies with meaningful Current Ratio only.
PBYI' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 6.31 Max: 91.42
Current: 6.31
1
91.42
Quick Ratio 6.31
PBYI's Quick Ratio is ranked higher than
66% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. PBYI: 6.31 )
Ranked among companies with meaningful Quick Ratio only.
PBYI' s Quick Ratio Range Over the Past 10 Years
Min: 1  Med: 6.31 Max: 91.42
Current: 6.31
1
91.42

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.30
PBYI's 3-Year Average Share Buyback Ratio is ranked higher than
60% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. PBYI: -8.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PBYI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -112.2  Med: -47.6 Max: -4.2
Current: -8.3
-112.2
-4.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 7.37
PBYI's Price-to-Net-Cash is ranked lower than
56% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. PBYI: 7.37 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PBYI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.69  Med: 13.98 Max: 60.47
Current: 7.37
4.69
60.47
Price-to-Net-Current-Asset-Value 7.10
PBYI's Price-to-Net-Current-Asset-Value is ranked lower than
56% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. PBYI: 7.10 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PBYI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.26  Med: 13.42 Max: 55.83
Current: 7.1
4.26
55.83
Price-to-Tangible-Book 6.54
PBYI's Price-to-Tangible-Book is ranked lower than
64% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. PBYI: 6.54 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PBYI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.17  Med: 12.36 Max: 49.4
Current: 6.54
4.17
49.4
Earnings Yield (Greenblatt) % -24.03
PBYI's Earnings Yield (Greenblatt) % is ranked lower than
80% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. PBYI: -24.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PBYI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1114.41  Med: 0 Max: 0
Current: -24.03
-1114.41
0

More Statistics

EPS (TTM) $ -8.29
Beta0.17
Short Percentage of Float49.14%
52-Week Range $19.74 - 73.27
Shares Outstanding (Mil)36.95

Analyst Estimate

Dec18 Dec19
Revenue (Mil $) 411 607
EPS ($) -0.44 2.81
EPS without NRI ($) -0.44 2.81
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PBYI

Headlines

Articles On GuruFocus.com
Sam Isaly Purchases Stake in Puma Biotechnology May 03 2016 
Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 

More From Other Websites
Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug Apr 18 2017
Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant... Apr 17 2017
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant... Apr 04 2017
Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with... Apr 02 2017
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant,... Apr 02 2017
Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with... Apr 02 2017
Finding Bullish and Bearish Market Reversals Mar 20 2017
7 Stocks Trending Up With Monster Volume Mar 09 2017
Puma Leads Massive Biotech Surge As Esperion Hits 15-Month High Mar 08 2017
Kroger, Shake Shack and Puma dip; Monster Beverage gains Mar 02 2017
Puma (PBYI) Q4 Loss Wider than Expected, Neratinib in Focus Mar 02 2017
Why Puma Biotechnology Inc. Got Hammered Today Mar 02 2017
Puma Biotechnology to Present at Cowen’s Health Care Conference Mar 02 2017
Puma Plunges on Breast Cancer Drug Update Mar 02 2017
Top Biotech Stocks With FDA Decisions in 2017 Mar 02 2017
Puma Biotech shares plummet 26% after Roche reports positive results for late-stage breast cancer... Mar 02 2017
Roche Shares Soar, Puma Bio Sinks on Perjeta Breast Cancer Study Win Mar 02 2017
Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017 Mar 01 2017
Puma Biotechnology Provides Update on Review of Marketing Authorisation Application for PB272 Mar 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)